key: cord-1035585-kzve19j0
authors: Yau, Kevin; Abe, Kento T.; Naimark, David; Oliver, Matthew J.; Perl, Jeffrey; Leis, Jerome A.; Bolotin, Shelly; Tran, Vanessa; Mullin, Sarah I.; Shadowitz, Ellen; Gonzalez, Anny; Sukovic, Tatjana; Garnham-Takaoka, Julie; de Launay, Keelia Quinn; Takaoka, Alyson; Straus, Sharon E.; McGeer, Allison J.; Chan, Christopher T.; Colwill, Karen; Gingras, Anne-Claude; Hladunewich, Michelle A.
title: Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis
date: 2021-09-02
journal: JAMA Netw Open
DOI: 10.1001/jamanetworkopen.2021.23622
sha: 7f977523e4aeea8ea3451c0f197d212ca8113cc0
doc_id: 1035585
cord_uid: kzve19j0

IMPORTANCE: Patients undergoing hemodialysis have a high mortality rate associated with COVID-19, and this patient population often has a poor response to vaccinations. Randomized clinical trials for COVID-19 vaccines included few patients with kidney disease; therefore, vaccine immunogenicity is uncertain in this population. OBJECTIVE: To evaluate the SARS-CoV-2 antibody response in patients undergoing chronic hemodialysis following 1 vs 2 doses of BNT162b2 COVID-19 vaccination compared with health care workers serving as controls and convalescent serum. DESIGN, SETTING, AND PARTICIPANTS: A prospective, single-center cohort study was conducted between February 2 and April 17, 2021, in Toronto, Ontario, Canada. Participants included 142 patients receiving in-center hemodialysis and 35 health care worker controls. EXPOSURES: BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine. MAIN OUTCOMES AND MEASURES: SARS-CoV-2 IgG antibodies to the spike protein (anti-spike), receptor binding domain (anti-RBD), and nucleocapsid protein (anti-NP). RESULTS: Among the 142 participants undergoing maintenance hemodialysis, 94 (66%) were men; median age was 72 (interquartile range, 62-79) years. SARS-CoV-2 IgG antibodies were measured in 66 patients receiving 1 vaccine dose following a public health policy change, 76 patients receiving 2 vaccine doses, and 35 health care workers receiving 2 vaccine doses. Detectable anti-NP suggestive of natural SARS-CoV-2 infection was detected in 15 of 142 (11%) patients at baseline, and only 3 patients had prior COVID-19 confirmed by reverse transcriptase polymerase chain reaction testing. Two additional patients contracted COVID-19 after receiving 2 doses of vaccine. In 66 patients receiving a single BNT162b2 dose, seroconversion occurred in 53 (80%) for anti-spike and 36 (55%) for anti-RBD by 28 days postdose, but a robust response, defined by reaching the median levels of antibodies in convalescent serum from COVID-19 survivors, was noted in only 15 patients (23%) for anti-spike and 4 (6%) for anti-RBD in convalescent serum from COVID-19 survivors. In patients receiving 2 doses of BNT162b2 vaccine, seroconversion occurred in 69 of 72 (96%) for anti-spike and 63 of 72 (88%) for anti-RBD by 2 weeks following the second dose and median convalescent serum levels were reached in 52 of 72 patients (72%) for anti-spike and 43 of 72 (60%) for anti-RBD. In contrast, all 35 health care workers exceeded the median level of anti-spike and anti-RBD found in convalescent serum 2 to 4 weeks after the second dose. CONCLUSIONS AND RELEVANCE: This study suggests poor immunogenicity 28 days following a single dose of BNT162b2 vaccine in the hemodialysis population, supporting adherence to recommended vaccination schedules and avoiding delay of the second dose in these at-risk individuals.

Abbreviations: HD, hemodialysis, HCW, health care worker; NP, nucleocapsid protein; RBD, receptor binding domain. a The median level of antigen in convalescent serum taken 21-115 days post-symptom onset is considered a robust antibody response and are 1.38,1.25, and 1.13 for anti-spike, anti-RBD, and anti-NP antibodies respectively. 

SARS-CoV-2 IgG spike, RBD, and NP Antibody Response Following One Versus Two Dose BNT162b2 Vaccine in Hemodialysis Patients Excluding Baseline Anti-NP Seroconversion

The samples are grouped into two cohorts who received one (n=63) or two doses (n=64) of vaccine after excluding individuals with Anti-NP seroconversion at baseline. Dots represent individual serum samples collected at the indicated times, and the samples from the same patients are connected by lines. Green dots indicate individuals with prior RT-PCR confirmed SARS-CoV-2 infection. Seroconversion threshold represents a positive test and are 0.19, 0.186, and 0.396 for anti-spike, anti-RDB, and anti-NP antibodies respectively. The median level of antigen in convalescent serum taken 21-115 days post-symptom onset is considered a robust antibody response and is 1.38, 1.25, and 1.13 for anti-spike, anti-RBD, and anti-NP antibodies respectively. Healthy control workers (n=35) received two doses of vaccines with serologic measurement 2-4 weeks following dose 2

This supplementary material has been provided by the authors to give readers additional information about their work.